title: Tacrolimus trough levels and level-to-dose ratio in stable renal transplant patients converted to a once-daily regimen.
abstract: Numerous evidence has been reported to support a safe 1:1 conversion from the twice-daily tacrolimus (Tac-T) to the once-daily tacrolimus regimen (Tac-O), but frequently there is a reduction in drug trough levels, which has been estimated by some authors to be about 20%. The relationship between Tac-O dosage and trough levels after conversion is not clear. The tacrolimus trough levels-to-dose ratio has been applied to better define the wide variability in doses and blood levels of tacrolimus. The aim of this study was to evaluate tacrolimus trough levels, tacrolimus daily dosage, and tacrolimus level-to-dose ratio during 1 year pre-postconversion follow-up in 31 stable kidney transplant patients who had received Tac-T therapy for over 6 months with stable renal function. They were converted to the same dosage of Tac-O. Patients before and after conversion were their own controls. The trough levels of tacrolimus showed a slight albeit significant reduction after conversion, remaining in the therapeutic range. Nineteen percent underwent an adjustment in total daily dosage after conversion versus 39% before conversion with no significant difference. No significant differences were detected in the total daily dose administered either by tacrolimus level-to-dose ratio before or after conversion. Kidney transplant recipients under Tac-O therapy were safely maintained using the same therapeutic monitoring as when receiving Tac-T.
authors.affiliation: Department of Clinical Medicine, Nephrology and Dialysis Unit, Sapienza University of Rome, Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Meçule
authors.forename: F
authors.initials: F
authors.lastname: Tinti
authors.forename: L
authors.initials: L
authors.lastname: Poli
authors.forename: A
authors.initials: A
authors.lastname: Bachetoni
authors.forename: I
authors.initials: I
authors.lastname: Umbro
authors.forename: I
authors.initials: I
authors.lastname: Nofroni
authors.forename: Q
authors.initials: Q
authors.lastname: Lai
authors.forename: R
authors.initials: R
authors.lastname: Pretagostini
authors.forename: P B
authors.initials: PB
authors.lastname: Berloco
authors.forename: A P
authors.initials: AP
authors.lastname: Mitterhofer
mesh_terms: D000328:Adult; D016009:Chi-Square Distribution; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D007558:Italy; D016030:Kidney Transplantation / Q000276:immunology; D008297:Male; D008875:Middle Aged; D016559:Tacrolimus / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus